drugset / Trial / NCT01207453

Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis

NCT01207453

RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether milnacipran reduces widespread, non-joint pain in patients with rheumatoid arthritis (RA). The investigators will conduct a double-blind randomized crossover trial in subjects with RA to test the hypothesis that milnacipran improves widespread, non-joint pain. The investigators will also use data from the trial to determine whether response to milnacipran is associated with pain-modulating mechanisms from the central nervous system. The investigators hypothesize that response to milnacipran will be greater among patients with impaired central pain mechanisms than among patients with intact central pain modulating mechanisms.

Timeline

Start
2011-01
Primary completion
2013-11
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Milnacipran Other / unclassified 50 mg Oral

Indications